Third-quarter fiscal 2010 results announced by Clinical Data

Clinical Data, Inc. (NASDAQ: CLDA) today announced the Company’s operational and financial results for its third fiscal quarter ended December 31, 2009, confirming its plans to submit a new drug application (NDA) for vilazodone for the treatment of depression this quarter.

“We have completed all of the clinical studies and related requirements to submit our NDA for vilazodone to the FDA this quarter”

Third Quarter and Recent Highlights

• Completed a public offering which generated approximately $47.4 million in gross proceeds
• Initiated the first Phase III trial of Stedivaze, a potential best-in-class coronary vasodilator for cardiac stress testing
• Increased FAMILION^® genetic testing gross revenue by 25% and improved gross margins from 35% to 53%, over the same period a year ago
• Launched the sixth FAMILION test used to diagnose or confirm familial heart disease and established a Scientific Advisory Board for cardiovascular genetics

“We have completed all of the clinical studies and related requirements to submit our NDA for vilazodone to the FDA this quarter,” said Drew Fromkin, Clinical Data’s President and Chief Executive Officer. “We are also advancing Stedivaze, our potential best-in-class coronary vasodilator, by enrolling patients in our first Phase III trial, and planning for the second Phase III study that we expect to begin later this year. Our preclinical programs are also moving forward, and we anticipate filing an investigational new drug application for at least one of these compounds in the next 12 to 18 months. We strengthened our financial resources in support of these programs and broadened our investor base through our successful public offering completed in November. We will also continue to pursue collaborative opportunities to advance our growing pipeline and supplement our financial resources.”

Financial Results for the Three Months Ended December 31, 2009

Gross revenue for the three months ended December 31, 2009 increased to $3.7 million, or 22%, up from $3.0 million when compared to the same period a year ago. This was primarily driven by an increase in gross sales from PGxHealth’s FAMILION tests of $719,000, or 25%, compared to the same period a year ago. The increase in gross revenue was partially offset by a rise in contractual allowances of $323,000, which represents an increase from 8% to 15% of gross genetic testing revenues, when compared to the third quarter of fiscal year 2009. This increase in contractual allowances is due to greater overall coverage policies, as well as the revenue mix of third-party payors and challenging macroeconomic conditions. The Company anticipates that future revenue will continue to be driven by expanding genetic test offerings, greater test adoption and increasing insurance coverage from third-party payors.

For the three-month period ended December 31, 2009, gross profit margins increased to 53%, up from 35% for the same period last year. The year-over-year improvement in gross margins was due to the increase in revenues, coupled with the realization of benefits from the significant investments the Company has made in infrastructure improvements. Gross margins are anticipated to continue to improve as revenues increase over time.

During the quarter, the Company expanded its genetic test offerings with the launch of its sixth genetic test, the FAMILION DCM Test for Dilated Cardiomyopathy (DCM). DCM is an inherited heart disease which is the leading cause of heart transplants and a possible cause of sudden cardiac death. The launch marked the third significant genetic test launched by PGxHealth, a division of Clinical Data, Inc., within the past 18 months.

Research and development expenses for the three months ended December 31, 2009 were $9.7 million, down from $15.1 million for the same period last year. This decrease was primarily attributable to the completion of the vilazodone safety trial and Phase III clinical program. These reductions were partially offset by costs incurred with advancing Stedivaze into the clinic, progressing preclinical programs, and commercial scale-up activities and preparations for the NDA submission for vilazodone. Ongoing research and development expenses are expected to increase due to the Stedivaze Phase III clinical trials and preparations for the commercialization of vilazodone.

During the quarter, the Company initiated a Phase III trial of Stedivaze (apadenoson) to evaluate its safety and efficacy for use as a pharmacologic stress agent in myocardial perfusion imaging (MPI), a method for evaluating blood flow to the heart. The Phase III ASPECT Trial (Apadenoson Single Photo Emission Computed Tomography) will also compare the tolerability of Stedivaze to adenosine, a standard pharmacologic stress agent used in MPI scans.

Sales and marketing expenses of $1.9 million were essentially flat when compared to the three months ended December 31, 2008. Expense in this area should continue at a comparable rate for the next several quarters as the Company continues to leverage its well-established FAMILION sales and marketing organization.

General and administrative expenses were $4.4 million, down from $5.0 million in the third quarter of last fiscal year. The decrease was primarily driven by a reduction in stock-based compensation, partially offset by an increase in the provision for uncollectable accounts largely due to the current economic conditions.

Financial Results for the Nine Months Ended December 31, 2009

Gross revenue for the nine months ended December 31, 2009 was $11.4 million, or 48%, an increase from $7.7 million for the nine months ended December 31, 2008. This increase was mainly driven by the growth in genetic tests sales of $3.7 million, up 51% when compared to the same period a year ago. Revenue has risen as a result of continued expansion of sales and marketing activities in fiscal 2009, the introduction of new and expanded tests and increased coverage policies from third-party payors. To date, third-party payor coverage for FAMILION tests is approximately 280 million lives in the U.S. As of December 31, 2009, PGxHealth was an approved Medicare provider and a Medicaid provider in most states. These increases in revenue were partially offset by an increase in contractual allowances of $1.1 million from $489,000, or 7% of gross genetic testing revenue, to $1.6 million, or 14% of gross genetic testing revenue. The increase in contractual allowances was due to an increase in coverage from third-party payors, as well as the mix of revenue from third-party payors.

Gross margins increased from 33% for the nine months ended December 31, 2008 to 52% for the nine months ended December 31, 2009. The improvement in gross margins from fiscal 2009 to 2010 was due to an increase in revenues, as well as the realization of benefits from infrastructure improvements and lab efficiencies implemented by the Company in fiscal 2009. Gross margins are expected to continue to improve as revenues increase, while costs, including personnel, equipment and facilities expense, remain essentially flat.

Research and development expenses were $30.1 million for the nine months ended December 31, 2009, down from $31.3 million when compared to the same a year ago. The decrease is primarily attributable to the completion of the safety and Phase III confirmatory trials for vilazodone. These reductions were partially offset by costs incurred with advancing Stedivaze into the clinic, progressing preclinical programs and the preparation of the NDA submission for vilazodone, which is expected to be made in the first quarter of calendar year 2010. Ongoing research and development expenses are expected to increase as the Company expands Phase III clinical trials for Stedivaze and prepares for the commercialization of vilazodone.

Sales and marketing expenses were $6.0 million for the nine months ended December 31, 2009, up from $5.7 million for the same period a year ago. The increase was mainly due to expenses relating to expanded sales and marketing activities during the past year. Sales and marketing expenses are expected to remain flat over the next several quarters as the Company leverages its established sales organization.

General and administrative expenses remained essentially flat at $14.9 million for the nine months ended December 31, 2009, compared to $14.7 million for the same period a year ago.

Cash and cash equivalents at December 31, 2009, were $70.2 million. This included net proceeds of $44.2 million raised from a public offering of 2,750,000 shares of common stock at a price of $17.25 per share completed in November 2009.